1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fibrosarcoma Global Clinical Trials Review, H1, 2014

Fibrosarcoma Global Clinical Trials Review, H1, 2014

  • March 2014
  • -
  • Global Data
  • -
  • 104 pages

Fibrosarcoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Fibrosarcoma Global Clinical Trials Review, H1, 2014" provides data on the Fibrosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fibrosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fibrosarcoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Fibrosarcoma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Fibrosarcoma 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Fibrosarcoma to Oncology Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Unaccomplished Trials of Fibrosarcoma 20
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Fibrosarcoma Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Novartis AG 27
Clinical Trial Overview of Novartis AG 27
Oncolytics Biotech Inc. 28
Clinical Trial Overview of Oncolytics Biotech Inc. 28
Daiichi Sankyo Company, Limited 29
Clinical Trial Overview of Daiichi Sankyo Company, Limited 29
Celgene Corporation 30
Clinical Trial Overview of Celgene Corporation 30
Clinical Trial Overview of Top Institutes / Government 31
National Cancer Institute 31
Clinical Trial Overview of National Cancer Institute 31
Children's Oncology Group 32
Clinical Trial Overview of Children's Oncology Group 32
Memorial Sloan Kettering Cancer Center 33
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 33
Societe Internationale d'Oncologie Pediatrique 34
Clinical Trial Overview of Societe Internationale d'Oncologie Pediatrique 34
Massachusetts General Hospital 35
Clinical Trial Overview of Massachusetts General Hospital 35
Assistance Publique - Hopitaux de Paris 36
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 36
National Taiwan University Hospital 37
Clinical Trial Overview of National Taiwan University Hospital 37
University of Michigan Comprehensive Cancer Center 38
Clinical Trial Overview of University of Michigan Comprehensive Cancer Center 38
Albert Einstein College of Medicine of Yeshiva University 39
Clinical Trial Overview of Albert Einstein College of Medicine of Yeshiva University 39
Five Key Clinical Profiles 40
Appendix 101
Abbreviations 101
Definitions 101
Research Methodology 102
Secondary Research 102
About GlobalData 103
Contact Us 103
Disclaimer 103
Source 104

List of Tables
Fibrosarcoma Therapeutics, Global, Clinical Trials by Region, 2014* 6
Fibrosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Fibrosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Fibrosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Fibrosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Fibrosarcoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Fibrosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Fibrosarcoma to Oncology Clinical Trials, G7 Countries (%), 2014* 13
Fibrosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Fibrosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Fibrosarcoma Therapeutics, Global, Clinical Trials by Phase, 2014* 16
Fibrosarcoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 17
Fibrosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Fibrosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 19
Fibrosarcoma Therapeutics, Global, Suspended Clinical Trials, 2014* 20
Fibrosarcoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 20
Fibrosarcoma Therapeutics, Global, Terminated Clinical Trials, 2014* 21
Fibrosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Fibrosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Fibrosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Fibrosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 25
Fibrosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 26
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 27
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncolytics Biotech Inc., 2014* 28
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 29
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 30
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 31
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 32
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 33
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Societe Internationale d'Oncologie Pediatrique, 2014* 34
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 35
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 36
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 37
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan Comprehensive Cancer Center, 2014* 38
Fibrosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Albert Einstein College of Medicine of Yeshiva University, 2014* 39

List of Figures
Fibrosarcoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Fibrosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Fibrosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Fibrosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Fibrosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Fibrosarcoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Fibrosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 12
Proportion of Fibrosarcoma to Oncology Clinical Trials, G7 Countries (%), 2014* 13
Fibrosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Fibrosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Fibrosarcoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 16
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 17
Fibrosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Fibrosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 19
Fibrosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Fibrosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
Fibrosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Fibrosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 25
Fibrosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 26
GlobalData Methodology 102

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.